Abstract
Background: A link between diabetes and Parkinson´s disease (PD) has been established by several reports. Consistent data report that people diagnosed with diabetes have demonstrated an enhanced risk of manifesting PD in their lifetime. The working principles involved in this link have been extensively discussed. Over the last decade, diabetes has been reported to be correlated with an increased risk of dementia, suggesting a potential role of diabetes, or insulin signalling dysregulations, in neurodegeneration. In addition, it is nowadays highly debated that dysregulations related to Ca2+ signalling may be an upstream issue which could also link diabetes and PD. Ca2+ and cAMP signalling pathways (Ca2+/cAMP signalling) control both the neurotransmitters/hormones release and neuronal death.
Conclusion: Considering our previous reports about Ca2+/cAMP signalling, the putative contribution of Ca2+/cAMP signalling in this link (between diabetes and PD) is discussed in this paper.
Keywords: Diabetes, Parkinson´s disease, Ca2+/cAMP signalling, Ca2+ channel blockers, pharmacotherapy, neurodegeneration.
[1]
Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson’s disease. Diabetes Care 2011; 34(4): 910-5.
[http://dx.doi.org/10.2337/dc10-1922] [PMID: 21378214]
[http://dx.doi.org/10.2337/dc10-1922] [PMID: 21378214]
[2]
Bergantin LB. Hypertension, Diabetes and neurodegenerative diseases: Is there a clinical link through the Ca2+/cAMP signalling interaction? Curr Hypertens Rev 2018.
[http://dx.doi.org/10.2174/1573402114666180817113242] [PMID: 30117399]
[http://dx.doi.org/10.2174/1573402114666180817113242] [PMID: 30117399]
[3]
Bergantin LB, Caricati-Neto A. Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca(2+)/cAMP intracellular signalling interaction. Eur J Pharmacol 2016; 788: 255-60.
[http://dx.doi.org/10.1016/j.ejphar.2016.06.034] [PMID: 27349146]
[http://dx.doi.org/10.1016/j.ejphar.2016.06.034] [PMID: 27349146]
[4]
Caricati-Neto A, Bergantin LB. From a “eureka insight” to a novel potential therapeutic target to treat Parkinson’s disease: The Ca2+/camp signalling interaction. J Syst Integr Neurosci 2017; 4
[http://dx.doi.org/10.15761/JSIN.1000187]
[http://dx.doi.org/10.15761/JSIN.1000187]
[5]
Tully PJ, Peters R, Pérès K, Anstey KJ, Tzourio C. Effect of SSRI and calcium channel blockers on depression symptoms and cognitive function in elderly persons treated for hypertension: three city cohort study. Int Psychogeriatr 2018; 30(9): 1345-54.
[http://dx.doi.org/10.1017/S1041610217002903] [PMID: 29559030]
[http://dx.doi.org/10.1017/S1041610217002903] [PMID: 29559030]
[6]
Lasram MM, Dhouib IB, Annabi A, El Fazaa S, Gharbi N. 2014; A
review on the molecular mechanisms involved in insulin resistance
induced by organophosphorus pesticides 322: 1-13.
[http://dx.doi.org/10.1016/j.tox.2014.04.009]
[http://dx.doi.org/10.1016/j.tox.2014.04.009]
[7]
Juntarawijit C, Juntarawijit Y. Association between diabetes and pesticides: a case-control study among Thai farmers. Environ Health Prev Med 2018; 23(1): 3.
[http://dx.doi.org/10.1186/s12199-018-0692-5]
[http://dx.doi.org/10.1186/s12199-018-0692-5]
[8]
Son H-K, Kim S-A, Kang J-H, et al. Strong associations between low-dose organochlorine pesticides and type 2 diabetes in Korea. Environ Int 2010; 36(5): 410-4.
[http://dx.doi.org/10.1016/j.envint.2010.02.012] [PMID: 20381150]
[http://dx.doi.org/10.1016/j.envint.2010.02.012] [PMID: 20381150]
[9]
Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 2010; 67(5): 600-6.
[PMID: 20437557]
[PMID: 20437557]
[10]
Bergantin LB. Debating the “bidirectional link” between diabetes and depression through the Ca2+/cAMP signalling: Off-label effects of Ca2+ channel blockers. Pharmacol Res 2019; 141: 298-302.
[http://dx.doi.org/10.1016/j.phrs.2019.01.008] [PMID: 30639385]
[http://dx.doi.org/10.1016/j.phrs.2019.01.008] [PMID: 30639385]
[11]
Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat Disord 2006; 12(3): 185-9.
[http://dx.doi.org/10.1016/j.parkreldis.2005.09.004] [PMID: 16364673]
[http://dx.doi.org/10.1016/j.parkreldis.2005.09.004] [PMID: 16364673]
[12]
Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 2006; 37(5): 1184-8.
[http://dx.doi.org/10.1161/01.STR.0000217384.03237.9c] [PMID: 16574924]
[http://dx.doi.org/10.1161/01.STR.0000217384.03237.9c] [PMID: 16574924]
[13]
D’Amelio M, Ragonese P, Callari G, et al. Diabetes preceding Parkinson’s disease onset. A case-control study. Parkinsonism Relat Disord 2009; 15(9): 660-4.
[http://dx.doi.org/10.1016/j.parkreldis.2009.02.013] [PMID: 19356970]
[http://dx.doi.org/10.1016/j.parkreldis.2009.02.013] [PMID: 19356970]
[14]
Bergantin LB, Caricati-Neto A. Advances for the pharmacotherapy of depression - Presenting the rising star: Ca2+/camp signaling interaction. J Syst Integr Neurosci 2017; 3
[http://dx.doi.org/10.15761/JSIN.1000161]
[http://dx.doi.org/10.15761/JSIN.1000161]
[15]
Bergantin LB, Souza CF, Ferreira RM, et al. Novel model for “calcium paradox” in sympathetic transmission of smooth muscles: role of cyclic AMP pathway. Cell Calcium 2013; 54(3): 202-12.
[http://dx.doi.org/10.1016/j.ceca.2013.06.004] [PMID: 23849429]
[http://dx.doi.org/10.1016/j.ceca.2013.06.004] [PMID: 23849429]
[16]
Sommer N, Löschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995; 1(3): 244-8.
[http://dx.doi.org/10.1038/nm0395-244] [PMID: 7585041]
[http://dx.doi.org/10.1038/nm0395-244] [PMID: 7585041]
[17]
Xiao L, O’Callaghan JP, O’Donnell JM. Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test. J Pharmacol Exp Ther 2011; 338(2): 641-7.
[http://dx.doi.org/10.1124/jpet.111.179358] [PMID: 21566211]
[http://dx.doi.org/10.1124/jpet.111.179358] [PMID: 21566211]
[18]
Caricati-Neto A, García AG, Bergantin LB. Pharmacological implications of the Ca(2+)/cAMP signaling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders. Pharmacol Res Perspect 2015; 3(5)e00181
[http://dx.doi.org/10.1002/prp2.181] [PMID: 26516591]
[http://dx.doi.org/10.1002/prp2.181] [PMID: 26516591]
[19]
Caricati-Neto A, Bergantin LB. Pharmacological modulation of neural Ca2+/camp signaling interaction as therapeutic goal for treatment of Alzheimer’s disease. J Syst Integr Neurosci 2017; 3
[http://dx.doi.org/10.15761/JSIN.1000185]
[http://dx.doi.org/10.15761/JSIN.1000185]
[20]
Caricati-Neto A, Bergantin LB. The passion of a scientific discovery: the “calcium paradox” due to Ca2+/camp interaction. J Syst Integr Neurosci 2017; 3
[http://dx.doi.org/10.15761/JSIN.1000186]
[http://dx.doi.org/10.15761/JSIN.1000186]
[21]
Khodneva Y, Shalev A, Frank SJ, Carson AP, Safford MM. Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study. Diabetes Res Clin Pract 2016; 115: 115-21.
[http://dx.doi.org/10.1016/j.diabres.2016.01.021] [PMID: 26818894]
[http://dx.doi.org/10.1016/j.diabres.2016.01.021] [PMID: 26818894]
[22]
Xu G, Chen J, Jing G, Shalev A. Preventing β-cell loss and diabetes with calcium channel blockers. Diabetes 2012; 61(4): 848-56.
[http://dx.doi.org/10.2337/db11-0955] [PMID: 22442301]
[http://dx.doi.org/10.2337/db11-0955] [PMID: 22442301]
[23]
Henquin JC. The interplay between cyclic AMP and ions in the stimulus-secretion coupling in pancreatic B-cells. Arch Int Physiol Biochim 1985; 93(1): 37-48.
[http://dx.doi.org/10.3109/13813458509104514] [PMID: 2409943]
[http://dx.doi.org/10.3109/13813458509104514] [PMID: 2409943]
[24]
Bratanova-Tochkova TK, Cheng H, Daniel S, et al. Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. Diabetes 2002; 51(Suppl. 1): S83-90.
[http://dx.doi.org/10.2337/diabetes.51.2007.S83] [PMID: 11815463]
[http://dx.doi.org/10.2337/diabetes.51.2007.S83] [PMID: 11815463]
[25]
Sharp GW. The adenylate cyclase-cyclic AMP system in islets of Langerhans and its role in the control of insulin release. Diabetologia 1979; 16(5): 287-96.
[http://dx.doi.org/10.1007/BF01223617] [PMID: 37137]
[http://dx.doi.org/10.1007/BF01223617] [PMID: 37137]
[26]
Sutherland EW, Robison GA. The role of cyclic AMP in the control of carbohydrate metabolism. Diabetes 1969; 18(12): 797-819.
[http://dx.doi.org/10.2337/diab.18.12.797] [PMID: 4311899]
[http://dx.doi.org/10.2337/diab.18.12.797] [PMID: 4311899]
[27]
Fujita-Yoshigaki J. Divergence and convergence in regulated exocytosis: the characteristics of cAMP-dependent enzyme secretion of parotid salivary acinar cells. Cell Signal 1998; 10(6): 371-5.
[http://dx.doi.org/10.1016/S0898-6568(97)00178-2] [PMID: 9720759]
[http://dx.doi.org/10.1016/S0898-6568(97)00178-2] [PMID: 9720759]
[28]
Tengholm A. Cyclic AMP dynamics in the pancreatic β-cell. Ups J Med Sci 2012; 117(4): 355-69.
[http://dx.doi.org/10.3109/03009734.2012.724732] [PMID: 22970724]
[http://dx.doi.org/10.3109/03009734.2012.724732] [PMID: 22970724]
[29]
Paul KC, Jerrett M, Ritz B. Type 2 Diabetes Mellitus and Alzheimer's
Disease: Overlapping Biological Mechanisms and Environmental
Risk Factors Curr Environ Health Rep Review 2018; 5(1): 44-58.
[http://dx.doi.org/10.1007 / s40572-018-0176-1]
[http://dx.doi.org/10.1007 / s40572-018-0176-1]
Article Metrics
42
8